

Global Expansion of Pacific Northwest *Vibrio parahaemolyticus* Sequence Type 36

Michel Abanto, Ronnie G. Gavilan, Craig Baker-Austin, Narjol Gonzalez-Escalona, Jaime Martinez-Urtaza

We report transcontinental expansion of *Vibrio parahaemolyticus* sequence type 36 into Lima, Peru. From national collections, we identified 7 isolates from 2 different Pacific Northwest complex lineages that surfaced during 2011–2016. Sequence type 36 is likely established in environmental reservoirs. Systematic surveillance enabled detection of these epidemic isolates.

Compared with other major foodborne illnesses, *Vibrio parahaemolyticus* infections have been steadily increasing (1); thus, *V. parahaemolyticus* has become the leading cause of seafood-related bacterial infections globally. The US Centers for Disease Control and Prevention estimated that the average annual incidence of all *Vibrio* infections increased by 54% during 2006–2017 (2), and *V. parahaemolyticus* infections were responsible for a large percentage of this increase in the later years (3). *V. parahaemolyticus* is believed to be responsible for ≈35,000 human infections each year in the United States alone (4) and has been identified as the leading cause of foodborne infections in China since the 1990s (5).

In some areas of the world, the steady increase in local numbers of cases associated with *V. parahaemolyticus* has coincided with the overall geographic expansion of *V. parahaemolyticus* disease. *V. parahaemolyticus* cases are now being regularly reported in areas with little previous incidence, including South America and northern Europe (6,7). Although the precise circumstances and factors driving the growth in case numbers are unclear, the transition of *V. parahaemolyticus* disease from a regional to a more global pathogen has been directly connected with the emergence of isolates with epidemic potential.

V. parahaemolyticus and *V. cholerae* represent the only 2 documented instances of global expansion of human pathogenic marine bacteria (8). Pandemic *V. cholerae* emerged >50 years ago, and intercontinental expansion of *V. parahaemolyticus* began ≈25 years ago. *V. parahaemolyticus* sequence type (ST) 3 emerged in India in 1996 and rapidly underwent transcontinental dissemination, reaching almost all continents (9). ST3 causes infections worldwide and persists as the dominant type in some countries of Asia, including China (5).

ST3 was the only known example of *V. parahaemolyticus* transcontinental expansion until 2012, when a new type, ST36, was identified outside its endemic region (the Pacific Northwest of North America) (10). ST36 infections were initially reported in the northeastern United States, increasing the number of *V. parahaemolyticus* infections in this region (3). A few months later, they were reported in a single large outbreak in Spain (11). An in-depth genomewide analysis of representative isolates from the Pacific Northwest, northeastern United States, and Spain showed that ST36 is a highly dynamic population and that the *V. parahaemolyticus* strains causing infections in the northeastern United States had diverged from the original lineage in the Pacific Northwest over the course of the cross-continent eastward expansion (12). The strains in the northeastern United States and Spain arose from 2 distinctive ST36 populations. Although the international spread of this population is a concern, ST36 has not been documented outside of the United States since the outbreak in Spain in 2012 (11).

The Study

After the emergence of cholera in 1991 in Peru and re-emergence in 1998, both concurrent with El Niño events, the Peruvian National Institute of Health (Lima, Peru) implemented a contingency plan for preparedness to respond to every El Niño episode. This contingency plan involves intensive investigations of all *Vibrio* isolates acquired in clinical settings and enhanced monitoring

Author affiliations: University of La Frontera, Temuco, Chile (M. Abanto); Instituto Nacional de Salud, Lima, Peru (R.G. Gavilan); The Centre for Environment, Fisheries and Aquaculture Science, Weymouth, UK (C. Baker-Austin, J. Martinez-Urtaza); US Food and Drug Administration, College Park, Maryland, USA (N. Gonzalez-Escalona)

DOI: <https://doi.org/10.3201/eid2602.190362>

of environmental sources. Among the characterized *V. parahaemolyticus* isolates obtained over the course of surveillance, we identified 5 clinical ST36 isolates (3 in 2015 and 2 in 2016) from Lima (Table). After reviewing the *V. parahaemolyticus* isolates deposited in the historical collection of the Peruvian National Institute of Health over the past 30 years, we were able to identify 2 additional isolates (1 from a seawater sample collected in 2011 and 1 from a clinic in 2012).

Table. Sequence type 36 isolates identified in clinical settings and from environmental sources, Lima, Peru, 2011–2016

Isolate	Alias	Year	Source
CFSAN062371	3.369–15	2011	Environmental
CFSAN062362	1.004–13	2012	Clinical
CFSAN062300	3.252–16	2015	Clinical
CFSAN062366	1.147–15	2015	Clinical
CFSAN062373	1.146–15	2015	Clinical
CFSAN062273	1.210–16	2016	Clinical
CFSAN062350	1.166–15	2016	Clinical




Figure 1. Phylogenetic reconstruction of transcontinental spread of *Vibrio parahaemolyticus* sequence type 36, North America, Peru, and Spain, 1985–2016. Timeline was estimated with BEAST (<https://beast.community>) by applying a Bayesian skyline demographic model and uncorrelated lognormal molecular clock. Single-nucleotide polymorphisms were identified in core genomes after the removal of recombination. Branch colors represent the most probable geographic origin of the last common ancestor of the group. Dates at nodes show estimated divergence dates from most recent common ancestor. Old PNW is the ancestral population (last strain identified in 2002) of the PNW lineage complex, and the modern PNW lineage is the currently circulating PNW population. *Vibrio* classifications are indicated. ANE, Atlantic Northeast; PNW, Pacific Northwest; SAWE, South America–West Europe.

We performed a genomewide phylogenetic analysis of a global collection of 111 ST36 isolates (Appendix Table, <https://wwwnc.cdc.gov/EID/article/26/2/19-0362-App1.pdf>) obtained during the past 30 years from the United States (west and east coasts), Canada, Spain, and Peru. Results indicated that the isolates from Peru were of 2 different genetic variants (Figures 1, 2): 5 clustered with the modern (i.e., currently circulating) Pacific Northwest lineage, and 2 clustered in a distinctive group comprising isolates from the 2012 outbreak in Spain. Analysis of the phylodynamics of transmission by Bayesian inference suggested the existence of 2 independent and almost contemporary introductions of ST36 into Peru in 2011, both originating from 2 distinct modern Pacific Northwest variants. The group comprising isolates from Peru and Spain appeared to have diverged from a common ancestor around 2004. Considering the number of years from the last common ancestor of both Peru

lineages and that other closely related genetic variants are absent from the dataset, intermediary populations might exist in regions not yet scrutinized.

The identification of ST36 in Peru provides additional evidence of the extraordinary dynamics of *Vibrio* infections in this region. Since the emergence of cholera in 1991 and the subsequent implementation of an active surveillance system for *Vibrio* diseases in Peru, several instances of emergence of major epidemic clones of *V. parahaemolyticus* have been reported in the country. Although the sources and routes of introduction of these foreign clones remain yet undetermined, a growing body of evidence has linked the epidemic dynamics and spreading of disease in this particular region of South America to El Niño (13). During the past 30 years, the emergence of cases in Peru associated with new clones of *Vibrio* has been sharply influenced by the onset of El Niño conditions, which has also shaped the extent and severity of epidemics




Figure 2. Transcontinental spread of *Vibrio parahaemolyticus* sequence type 36, North America, Peru, and Spain, 1985–2016. Timeline was estimated by using BEAST (Bayesian evolutionary analysis by sampling trees). Years on map indicate the inferred dates of arrival of *V. parahaemolyticus* sequence type 36 to that country. Old Pacific Northwest is the ancestral population (last strain identified in 2002) of the Pacific Northwest lineage complex, which also includes the modern (i.e., currently circulating) Pacific Northwest lineage, Pacific Northwest lineage 2, Atlantic Northeast lineage, and the South America–West Europe group.

(14,15). The arrival of extraordinary weather conditions brought on by El Niño (i.e., a combination of heavy rains and heat waves) provides the ideal conditions for the proliferation of *Vibrio* spp. in the environment. These circumstances, along with disruption of sanitary infrastructure caused by floods and landslides, can help generate the perfect conditions for the explosive emergence of *Vibrio* diseases.

Despite the evidence connecting the epidemiology of *Vibrio* in Peru to El Niño, little is known about the mechanisms of global dispersal and introduction of foreign epidemic clones into the region. Ballast water from cargo ships and marine heat waves have been associated with some instances of disease emergence elsewhere (12). Another mechanism that might be involved in the dispersal of *V. parahaemolyticus* populations is the international trade of shellfish, which was suggested to facilitate the introduction of ST36 into the United States and Spain (12).

Conclusions

We report the transcontinental expansion of ST36 *V. parahaemolyticus* into South America. The presence of ST36 in clinical and environmental settings in Peru emphasizes the exceptional epidemic potential of the Pacific Northwest complex and *V. parahaemolyticus* as a human pathogen. The long-term persistence and presence of environmental isolates suggest the successful establishment of ST36 in environmental reservoirs. ST36's ability for intercontinental dispersal, along with its highly pathogenic nature (1), make this *Vibrio* population a major public health concern. Furthermore, Peru has shown that implementation of systematic surveillance for *Vibrio* species can facilitate the detection of emerging transnational epidemic strains. This strategy will play a crucial role under exceptional climatic conditions, such as those generated by El Niño, where enhanced risk for outbreaks is likely.

This work was funded through the Natural Environment Research Council project NE/P004121/1.

About the Author

Dr. Abanto is a scientist at the Scientific and Technological Bioresource Nucleus, Universidad de la Frontera, Temuco, Chile. His research interests include emerging microbes, genomic epidemiology, and the use of integrative and efficient computational methods applied to the study of the epidemiology and ecology of microorganisms.

References

- Martinez-Urtaza J, Bowers JC, Trinanes J, DePaola A. Climate anomalies and the increasing risk of *Vibrio parahaemolyticus* and *Vibrio vulnificus* illnesses. *Food Res Int*. 2010;43:1780–90. <https://doi.org/10.1016/j.foodres.2010.04.001>

- Marder EP, Griffin PM, Cieslak PR, Dunn J, Hurd S, Jervis R, et al. Preliminary incidence and trends of infections with pathogens transmitted commonly through food – Foodborne Diseases Active Surveillance Network, 10 U.S. sites, 2006–2017. *MMWR Morb Mortal Wkly Rep*. 2018;67:324–8. <https://doi.org/10.15585/mmwr.mm6711a3>
- Newton AE, Garrett N, Stroika SG, Halpin JL, Turnsek M, Mody RK; Centers for Disease Control and Prevention. Increase in *Vibrio parahaemolyticus* infections associated with consumption of Atlantic Coast shellfish – 2013. *MMWR Morb Mortal Wkly Rep*. 2014;63:335–6.
- Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, et al. Foodborne illness acquired in the United States – major pathogens. *Emerg Infect Dis*. 2011;17:7–15. <https://doi.org/10.3201/eid1701.P11101>
- Li Y, Xie X, Shi X, Lin Y, Qiu Y, Mou J, et al. *Vibrio parahaemolyticus*, southern coastal region of China, 2007–2012. *Emerg Infect Dis*. 2014;20:685–8. <https://doi.org/10.3201/eid2004.130744>
- González-Escalona N, Cachicas V, Acevedo C, Rioseco ML, Vergara JA, Cabello F, et al. *Vibrio parahaemolyticus* diarrhea, Chile, 1998 and 2004. *Emerg Infect Dis*. 2005;11:129–31. <https://doi.org/10.3201/eid1101.040762>
- Baker-Austin C, Trinanes JA, Salmenlinna S, Löfdahl M, Siitonen A, Taylor NG, et al. Heat wave-associated vibriosis, Sweden and Finland, 2014. *Emerg Infect Dis*. 2016;22:1216–20. <https://doi.org/10.3201/eid2207.151996>
- Baker-Austin C, Oliver JD, Alam M, Ali A, Waldor MK, Qadri F, et al. *Vibrio* spp. infections. *Nat Rev Dis Primers*. 2018;4:8. <https://doi.org/10.1038/s41572-018-0005-8>
- Nair GB, Ramamurthy T, Bhattacharya SK, Dutta B, Takeda Y, Sack DA. Global dissemination of *Vibrio parahaemolyticus* serotype O3:K6 and its serovariants. *Clin Microbiol Rev*. 2007;20:39–48. <https://doi.org/10.1128/CMR.00025-06>
- Martinez-Urtaza J, Baker-Austin C, Jones JL, Newton AE, Gonzalez-Aviles GD, DePaola A. Spread of Pacific Northwest *Vibrio parahaemolyticus* strain. *N Engl J Med*. 2013;369:1573–4. <https://doi.org/10.1056/NEJMc1305535>
- Martinez-Urtaza J, Powell A, Jansa J, Rey JL, Montero OP, Campello MG, et al. Epidemiological investigation of a foodborne outbreak in Spain associated with U.S. West Coast genotypes of *Vibrio parahaemolyticus*. *Springerplus*. 2016;5:87. <https://doi.org/10.1186/s40064-016-1728-1>
- Martinez-Urtaza J, van Aerle R, Abanto M, Haendiges J, Myers RA, Trinanes J, et al. Genomic variation and evolution of *Vibrio parahaemolyticus* ST36 over the course of a transcontinental epidemic expansion. *MBio*. 2017;8:e01425–17. <https://doi.org/10.1128/mBio.01425-17>
- Martinez-Urtaza J, Trinanes J, Gonzalez-Escalona N, Baker-Austin C. Is El Niño a long-distance corridor for waterborne disease? *Nat Microbiol*. 2016;1:16018. <https://doi.org/10.1038/nmicrobiol.2016.18>
- Speelmon EC, Checkley W, Gilman RH, Patz J, Calderon M, Manga S. Cholera incidence and El Niño-related higher ambient temperature. *JAMA*. 2000;283:3072–4. <https://doi.org/10.1001/jama.283.23.3068i>
- Martinez-Urtaza J, Huapaya B, Gavilan RG, Blanco-Abad V, Ansedé-Bermejo J, Cadarso-Suarez C, et al. Emergence of Asiatic vibrio diseases in South America in phase with El Niño. *Epidemiology*. 2008;19:829–37. <https://doi.org/10.1097/EDE.0b013e3181883d43>

Address for correspondence: Jaime Martinez-Urtaza, The Centre for Environment, Fisheries and Aquaculture Science, The Nothe, Barrack Road, Weymouth, Dorset DT4 8UB, UK; email: jaime.martinez-urtaza@cefes.co.uk

Global Expansion of Pacific Northwest *Vibrio parahaemolyticus* Sequence Type 36

Appendix

Appendix Table. List of *Vibrio parahaemolyticus* ST36 strains used in this study and their metadata

Strain	Alias	Province or city	Country	Year	Source	Accession No.
09-3219	09-3219	British Columbia	Canada	2009	Clinical	NZ_LRST00000000
09-3216	09-3216	British Columbia	Canada	2009	Clinical	JXVJ00000000
F4395	F4395	British Columbia	Canada	2006	Clinical	NZ_LRFU01000000
H11523	H11523	British Columbia	Canada	2006	Clinical	LRFY01000000
10-7197	10-7197	British Columbia	Canada	2008	Clinical	JXUX00000000
10-4245	10-4245	British Columbia	Canada	2006	Clinical	JXVH00000000
10-4248	10-4248	British Columbia	Canada	2006	Clinical	JXVD00000000
10-4242	10-4242	British Columbia	Canada	2006	Clinical	JXVH00000000
10-4246	10-4246	British Columbia	Canada	2006	Clinical	JXVF00000000
H18983	H18983	British Columbia	Canada	2006	Clinical	NZ_LRST00000000
T8994	T8994	British Columbia	Canada	2006	Clinical	NZ_LRGA01000000
10-4274	10-4274	British Columbia	Canada	2005	Clinical	JXVC00000000
K5433	CDC_K5433	Washington	USA	2007	Clinical	NZ_MIUR01000000
K5345W	CDC_K5345W	Iowa	USA	2007	Clinical	NZ_MIUN01000000
M59787	M59787	British Columbia	Canada	2006	Clinical	LRJZ01000000
AM51866	CDC4967	Washington	USA	2012	Clinical	LHRM00000000
VpG-12	CDC4902	Washington	USA	2012	Clinical	LHRG00000000
AM51867	CDC4970	Washington	USA	2012	Clinical	LHRN00000000
AM47612	CDCAM47612	Washington	USA	2011	Clinical	LHRI00000000
C147	C147	British Columbia	Canada	2008	Clinical	LPVM01000000
A5Z652	A5Z652	British Columbia	Canada	2005	Clinical	LQCE01000000
10-4241	10-4241	British Columbia	Canada	2006	Clinical	JXVI00000000
3256	3256	Washington	USA	2007	Clinical	AZGS00000000
H64024	H64024	British Columbia	Canada	2006	Clinical	LRFZ01000000
C143	C143	British Columbia	Canada	2008	Clinical	LPVB01000000
C144	C144	British Columbia	Canada	2008	Clinical	LPVC01000000
K5280	CDCK5280	Washington	USA	2007	Clinical	LHQX00000000
K5281	CDC_K5281	Washington	USA	2007	Clinical	NZ_MIUB01000000
K5512	CDC_K5512	Oklahoma	USA	2007	Clinical	NZ_MIUZ01000000
K5278	CDC_K5278	Washington	USA	2007	Clinical	NZ_MITY01000000
K5437	CDC_K5437	Washington	USA	2007	Clinical	NZ_MIUT01000000
12310	12310	Washington	USA	2006	Clinical	AYXP00000000
K5457	CDC_K5457	Washington	USA	2007	Clinical	NZ_MIUX01000000
846	846	Washington	USA	2007	Environmental	NZ_AOOX00000000
12315	12315	Washington	USA	2006	Clinical	NZ_AOPF00000000
K5429	CDC_K5429	Nevada	USA	2007	Clinical	NZ_MIUQ01000000
K5308	CDC_K5308	Alaska	USA	2007	Clinical	NZ_MIUE01000000
A5Z924	A5Z924	British Columbia	Canada	2005	Clinical	LQCV01000000
A5Z878	A5Z878	British Columbia	Canada	2005	Clinical	NZ_LQCT00000000
AM51816	CDC_M12X03280	California	USA	2012	Clinical	LHRL00000000
10-4247	10-4247	British Columbia	Canada	2006	Clinical	JXVE01000000
K5346	CDC_K5346	Pennsylvania	USA	2007	Clinical	NZ_MIUO00000000
CFSAN062366	1.147-15	Lima	Peru	2015	Clinical	SRR8103881
CFSAN062373	1.146-15	Lima	Peru	2015	Clinical	SRR8103882
CFSAN062300	3.252-16	Lima	Peru	2015	Clinical	SRR8103883
CFSAN062350	1.166-15	Lima	Peru	2016	Clinical	SRR8103885
CFSAN062362	1.004-13	Lima	Peru	2012	Clinical	WSRX00000000
MAVP-V	MAVP-V	Massachusetts	USA	2011	Clinical	NZ_LBHO00000000
10-4288	10-4288	British Columbia	Canada	2003	Clinical	JXVB00000000
04-1290	04-1290	British Columbia	Canada	2004	Clinical	NZ_JXVK01000000
MAVP-45	MAVP-45	Massachusetts	USA	2013	Clinical	NZ_LBHN01000000
MAVP-26	MAVP-26	Massachusetts	USA	2013	Clinical	NZ_LBHD01000000
VpG-1	CDCK4639-1	New York	USA	2006	Clinical	LHRH00000000
K4639W	CDC_K4639W	New York	USA	2006	Clinical	NZ_MITA00000000

Strain	Alias	Province or city	Country	Year	Source	Accession No.
VP42	CFSAN007460	Maryland	USA	2013	Clinical	JNTS02000000
VP36	CFSAN006133	Maryland	USA	2013	Clinical	JNTP02000000
VP12	CFSAN006129	Maryland	USA	2012	Clinical	JNTM02000000
VP40	CFSAN006135	Maryland	USA	2013	Clinical	JNTR02000000
VP38	CFSAN006134	Maryland	USA	2013	Clinical	JNTQ02000000
VP43	CFSAN007461	Maryland	USA	2013	Clinical	JNTT02000000
AM51556	CDC_JBI 12000789	Florida	USA	2012	Clinical	LHRK00000000
VP33	CFSAN006132	Maryland	USA	2013	Clinical	JNTO02000000
CDC-121898	CFSAN018775	New Jersey	USA	2012	Clinical	LHRP00000000
VpG-10	CT_220206001	Connecticut	USA	2012	Clinical	LHRE00000000
VpG-3	MA_12EN2941	Massachusetts	USA	2012	Clinical	LHRC00000000
VpG-4	MA_12EN2945	Massachusetts	USA	2012	Clinical	LHRD00000000
CFSAN018777	CDC101325304	New York	USA	2012	Clinical	LHRQ00000000
VpG-6	CFSAN001597	Missouri	USA	2012	Clinical	LHRH01000000
CDC-M12-106	CDC_M12-108 G	Missouri	USA	2012	Clinical	LHQZ00000000
VpG-9	CA_M12X02735	California	USA	2012	Clinical	LHRF00000000
VP51	CFSAN026730	Maryland	USA	2013	Clinical	NZ_MRVC01000000
VP50	CFSAN026729	Maryland	USA	2013	Clinical	NZ_MRVB01000000
VP30	CFSAN006130	Maryland	USA	2013	Clinical	JNTV02000000
VP46	CFSAN007462	Maryland	USA	2013	Clinical	JNTU02000000
VpG-8	CA_M12X02764	California	USA	2012	Clinical	LHRA00000000
VpG-7	CA_M12X02763	California	USA	2012	Clinical	LHRB00000000
3324	3324	Washington	USA	2007	Clinical	NZ_AOPA00000000
K1461	K1461	Massachusetts	USA	2004	Clinical	NZ_JMMO01000000
VpG-11	CDCK5629	Georgia	USA	2007	Clinical	LHQY00000000
MAVP-36	MAVP-36	Massachusetts	USA	2013	Clinical	NZ_LBHE00000000
VP32	CFSAN006131	Maryland	USA	2013	Clinical	JNTN02000000
CFSAN022332	G31	Galicia	Spain	2012	Clinical	LHRT00000000
CFSAN022335	G36	Galicia	Spain	2012	Clinical	LHRV00000000
CFSAN022334	G37	Galicia	Spain	2012	Clinical	LHRU00000000
CFSAN022331	G30	Galicia	Spain	2012	Clinical	LHRS00000000
CFSAN022336	G35	Galicia	Spain	2012	Clinical	LHRW00000000
CFSAN022330	G25	Galicia	Spain	2012	Clinical	LHRR00000000
CFSAN062371	3.369-15	Lima	Peru	2011	Environmental	SRR8103880
CFSAN062273	1.210-16	Lima	Peru	2016	Clinical	SRR8103884
10-4298	10-4298	British Columbia	Canada	2001	Clinical	JXUZ00000000
CFSAN018774	CDCA8962	Massachusetts	USA	2008	Clinical	LHRO00000000
A1EZ679	A1EZ679	British Columbia	Canada	2001	Clinical	NZ_LRSZ00000000
A2EZ715	A2EZ715	British Columbia	Canada	2002	Clinical	NZ_LRFQ00000000
10-4293	10-4293	British Columbia	Canada	2002	Clinical	JXVA00000000
A1EZ919	A1EZ919	British Columbia	Canada	2001	Clinical	NZ_LNTX00000000
A2EZ523	A2EZ523	British Columbia	Canada	2002	Clinical	NZ_LRTA00000000
10329	10329	Washington	USA	1998	Clinical	JWSS00000000
10-4303	10-4303	British Columbia	Canada	2000	Clinical	JXUY00000000
A0EZ608	A0EZ608	British Columbia	Canada	2000	Clinical	NZ_LRFM00000000
EN9901310	EN9901310	Washington	USA	1999	Clinical	NZ_AOPL00000000
10290	CFSAN001613	Washington	USA	1997	Clinical	JNUF02000000
O29-1-b	O29-1(b)	Washington	USA	1997	Environmental	JNTW02000000
A5Z905	A5Z905	British Columbia	Canada	2005	Clinical	NZ_LQCU00000000
10296	10296	Washington	USA	1997	Clinical	AYSP01000000
EN9701173	EN9701173	Washington	USA	1997	Clinical	NZ_AOPK00000000
NY-3483	NY-3483	New York	USA	1998	Clinical	JNUC02000000
48057	48057	Washington	USA	1990	Clinical	JNTX02000000
VP43-1A	CFSAN001621	Washington	USA	1992	Environmental	LHQV00000000
JJ21-1C	CFSAN001615	Washington	USA	1990	Environmental	LHPD00000000
48291	48291	Washington	USA	1990	Clinical	JNUA02000000
F11-3A	F11-3A	Washington	USA	1988	Environmental	JNUB02000000

*ST, sequence type.